Sandoz targets more than double net sales by 2035
Sandoz says it aims to more than double net sales from 2025 to 2035 and to achieve a core EBITDA margin above 30% by 2035, while keeping its commitment to the midterm outlook to 2028.
Story updates
05:46:36 AM UTC
SquawkNews
Sandoz BX:D8Y aims to more than double net sales from 2025 to 2035, the Swiss drug maker said on Tuesday at its capital markets day, where it outlined its new Bio100 biosimilars strategy, pivoting its focus from generics to biosimilars."Our Bio100 ambitions are set to position biosimilars to become…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.